Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 3/20 | 0.36 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.36 |
| ▸ | AKR1B1 | P15121 | 5/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.32 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13173050 | 1.00 | LMNA (0.40) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL1105636 | 0.88 | KMT2A (0.55) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL28562582 | 0.88 | KMT2A (0.55) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL2614442 | 0.86 | KMT2A (0.56) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL14340364 | 0.86 | TDP1 (0.37) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL16500586 | 0.85 | KMT2A (0.40) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL18715387 | 0.85 | MAPT (0.40) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL19063420 | 0.85 | MEN1 (0.40) | LMNAMEN1MAPTTHRBHTT | |
| Bromide SCHEMBL5458771 | 0.84 | TDP1 (0.36) | LMNAMEN1MAPTTHRBHTT | |
| SCHEMBL10090439 | 0.84 | TDP1 (0.42) | LMNAMEN1MAPTTHRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140186875-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSIS | MONTANA STATE UNIVERSITY (US) | 2014-07-03 | — | — | US | disclosed |
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | NATIONAL SCIENCE FOUNDATION | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100252433-A1 | NOVEL OPTICAL LABELING MOLECULES FOR PROTEOMICS AND OTHER BIOLOGICAL ANALYSES | PTMS, CHAMP1, RAB5IF | LMNA 3234/4885MEN1 4213/4885MAPT 1476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.